Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca reports declines in revenues and operating profits in the 2011 first quarter, but expects its earnings per share will be boosted this year from tax and patent settlements.

You may also be interested in...

Hit By Earthquake and U.S. Restructuring, Shionogi Looks To Regroup In Time For Crestor Loss

TOKYO - Shionogi & Co. Ltd. is fighting a two-front battle, recovery from the March 2011 earthquake and tsunami in Northern Japan and restructuring of its U.S. acquisition. The company formulated a mid-term plan to address ways to buffer the September 2016 patent loss of Crestor (rosuvastatin), by far the company's most important drug, but setbacks in the U.S. raise doubts about the company's ability to counter the patent cliff

GSK Highlights R&D Productivity Gains In First Quarter

Although GlaxoSmithKline's global sales declined by 10% and EPS rose by 9% during the first quarter, the UK Big Pharma sees signs of increased R&D productivity.

Distributing Is Not Licensing: PDL BioPharma Loses Patent, Royalty Battle With MedImmune

A California federal court rules that a PDL patent claim is invalid and that MedImmune did not have to pay royalties on sales by its ex-U.S. distributor Abbott; MedImmune may seek repayment of $280 million in royalties.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts